Bevacizumab plus erlotinib versus erlotinib alone in Japenese patients

Furmonertinib versus gefitinib in treatment naive EGFR mutated non small cell lung cancer

7MO Oritinib a third generation EGFR tyrosine kinase inhibitor in locally advanced

Updated Analysis of NEJ009 Gefitinib Alone Versus Gefitinib Plus Chemotherapy

Randomized Trial of first Line Tyrosine Kinase Inhibitor with or without Radiotherapy

Sintilimab In Combination With Anlotinib In Non-Small Cell Lung Cancer Patients With Uncommon EGFR Mutations

Panel Discussion - EGFR mutant NSCLC 1st Line Long Term Outcomes

Simultaneous Tissue and Liquid Next-generation Sequencing after First-line EGFR Tyrosine Kinase Inhibitors Resistance in Advanced NSCLC

Real World Landscape of EGFR C797X Mutation as a Resistance Mechanism

A phase II study of Atezolizumab in combination with bevacizumab

Durvalumab plus chemotherapy in patients with advanced EGFR mutation positive

A Randomised phase II Study of Osimertinib and Bevacizumab Versus Bevacizumab

Capmatinib plus osimertinib versus platinumpermetrexed doublet Chemotherapy

BBT 176 A 4th Generation EGFR TKI for Progressed NSCLC After EGFR TKI Therapy

Panel Discussion - EGFR TKI Resistance

Optimization of treatment options for EGFR mutant Stage III Unresectable NSCLC

Once daily versus twice daily chemoradiation for limited stage small cell

CAPSTONE Trial

Primary analysis from the phase 2 study of continuous talazoparib TALA plus

Comparison of quality of life in patients randomized to high dose once daily QD

SKYCSRAPER 02 Primary results of a phase III randomized double blind

Panel Discussion - Optimal Management ES SCLC Case based Discussion

Development of a rural Comprehensive Cancer Centre

Role of Romiplostim in Chemotherapy induced Thrombocytopenia

Bevacizumab plus erlotinib versus erlotinib alone in Japenese patients

Furmonertinib versus gefitinib in treatment naive EGFR mutated non small cell lung cancer

7MO Oritinib a third generation EGFR tyrosine kinase inhibitor in locally advanced

Updated Analysis of NEJ009 Gefitinib Alone Versus Gefitinib Plus Chemotherapy

Randomized Trial of first Line Tyrosine Kinase Inhibitor with or without Radiotherapy

Sintilimab In Combination With Anlotinib In Non-Small Cell Lung Cancer Patients With Uncommon EGFR Mutations

Panel Discussion - EGFR mutant NSCLC 1st Line Long Term Outcomes

Simultaneous Tissue and Liquid Next-generation Sequencing after First-line EGFR Tyrosine Kinase Inhibitors Resistance in Advanced NSCLC

Real World Landscape of EGFR C797X Mutation as a Resistance Mechanism

A phase II study of Atezolizumab in combination with bevacizumab

Durvalumab plus chemotherapy in patients with advanced EGFR mutation positive

A Randomised phase II Study of Osimertinib and Bevacizumab Versus Bevacizumab

Capmatinib plus osimertinib versus platinumpermetrexed doublet Chemotherapy

BBT 176 A 4th Generation EGFR TKI for Progressed NSCLC After EGFR TKI Therapy

Panel Discussion - EGFR TKI Resistance

Once daily versus twice daily chemoradiation for limited stage small cell

CAPSTONE Trial

Primary analysis from the phase 2 study of continuous talazoparib TALA plus

Comparison of quality of life in patients randomized to high dose once daily QD

SKYCSRAPER 02 Primary results of a phase III randomized double blind